ADTX News and Press, ADiTx Therapeutics Inc. From 03/07/24

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy PR Newswire -- New weight loss drugs like Ozempic, Wegovy and Zepbound may make oral birth co...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...

Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...

ESSA Pharma Inc. (EPIX) is expected to report $-0.17 for Q1 2024 QuidelOrtho Corp Com (QDEL) is expected to report $2.01 for Q4 2023 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 Portsmouth Square, Inc. (PRSI) is expected to report for Q2 2024 Similarweb Ltd. (SMWB) ...

2024-02-01 08:48:44 ET More on Evofem Biosciences Aditxt to acquire women’s health company Evofem Biosciences Seeking Alpha’s Quant Rating on Evofem Biosciences Historical earnings data for Evofem Biosciences Financial information for Evofem Bio...

Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 PR Newswire Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced More Than 60% from 2022 Levels SAN DIEGO ...

Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, has announced its acquisition of a portfolio of electroencephalography “EEG” brain monitoring technologies and devices formerly owned by Brain Scientific, Inc. The prod...

2024-01-30 08:39:35 ET More on Aditx Therapeutics Aditxt announces $6M private placement to fund its working capital Aditxt to acquire women’s health company Evofem Biosciences Seeking Alpha’s Quant Rating on Aditx Therapeutics Historical earnin...

The global EEG devices market was valued at $1.06 billion in 2022 and is anticipated to expand at a CAGR of 10.2% from 2023 to 2030 Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promisin...